Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Positive Phase 1 Trial Data in Non-Muscle Invasive Bladder Cancer (NMIBC) Presented at the 40^th Annual European Association of Urology Congress; Supports Front-Line Treatment Potential

Read more at globenewswire.com